Abstract: A method and apparatus for concurrency testing within a model-based testing environment is provided. One implementation involves concurrency testing within a model-based software system testing environment, by receiving concurrent test service requests; duplicating a model representing software under test, based on the number of requests; sending the concurrent requests to each of the duplicated models sequentially but in different orders; storing the outcomes of each of the models; comparing the outcomes from the models to the outcome from the software system under test; and if all comparisons fail, then indicating test failure.

Abstract: The use of a PPAR agonist in the manufacture of a medicament to increase ruminant serum glucose concentrations, and preferably, the use for the palliative, prophylactic or curative treatment of ruminant disease associated with reduced serum glucose concentration. The ruminant disease associated with reduced serum glucose concentration includes fatty liver syndrome, dystocia, immune dysfunction, impaired immune function, toxification, primary ketosis, secondary ketosis, downer cow syndrome, indigestion, inappetence, retained placenta, displaced abomasum, mastitis, (endo-)-metritis, infertility, low fertility, lameness, subacute rumen acidosis and inadequate nutrient intake associated with stress e.g. heat, poor housing, overcrowding, shipping, dominance or illness, and to increase milk quality and yield.

Abstract: Compounds according formula (I) A-G-Z-W and pharmaceutically acceptable salts, solvates or hydrates thereof; wherein, A is (C6-C10)aryl, (C6-C10)aryl-SO2, (C6-C10)aryl-CH2—, (C6-C10)arylcarbonyl, (C1-C9)heteroaryl, (C1-C9)heteroaryl-SO2—, (C1-C9)heteroaryl-CH2—; or (C1-C9)heteroarylcarbonyl; G is selected from the group consisting of: where B is (C6-C10)aryl or (C1-C9)heteroaryl, and X is CH2, SO2, or carbonyl; where X is CH2, SO2, or carbonyl; and R1 and R1? are each independently selected from H, CN, (C1-C8)alkyl-, and phenyl(CH2)—, wherein said alkyl and phenyl groups are optionally substituted; and where Z and W are as defined in the present Specificiation; and pharmaceutical compositions and methods useful to increase secretion of growth hormone(GH) from the anterior pituitary of mammals, including on a sustained release basis.

Abstract: The present invention relates to the use of an assay that measures receptor residence time of a ligand on its receptor in vitro for the identification of a ligand for that receptor predicted to be efficacious in vivo in the treatment of a disease that responds to modulation of that receptor's natural function.

Abstract: An assay method for determining whether an agent is capable of modulating the interaction of CCR5 and gp120 is disclosed. The method comprises incubating the agent with CCR5 and gp120 to form a first reaction mixture, and determining whether said agent modulates the interaction of CCR5 with gp120, wherein said gp120 is associated with CD4. In particular, the interaction is a low affinity binding.